STUDIES ON FUNGAL POLYSACCHARIDE .38. STRUCTURE AND ANTITUMOR-ACTIVITY OF THE LESS-BRANCHED DERIVATIVES OF AN ALKALI-SOLUBLE GLUCAN ISOLATED FROM OMPHALIA-LAPIDESCENS

被引:37
作者
SAITO, K [1 ]
NISHIJIMA, M [1 ]
OHNO, N [1 ]
YADOMAE, T [1 ]
MIYAZAKI, T [1 ]
机构
[1] TOKYO COLL PHARM, HACHIOJI, TOKYO 19203, JAPAN
关键词
LEIWAN (OMPHALIA-LAPIDESCENS); 6-O-BRANCHED (1-]3)-BETA-D-GLUCAN; SMITH-TYPE DEGRADATION; METHYLATION ANALYSIS; BRANCHING DEGREE; ANTITUMOR ACTIVITY;
D O I
10.1248/cpb.40.261
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The structure and antitumor activity of Smith-type degradation products (OL-2-I, OL-2-II and OL-2-III) of an alkali-soluble glucan, OL-2, isolated from a crude fungal drug ''Leiwan'' (Omphalia lapidescens) were investigated. Methylation analysis suggested that OL-2-I was a (1 --> 3)-beta-D-glucan with approximately one branch at every three main chain glucosyl units at each C-6 position; OL-2-II was a (1 --> 3)-beta-D-glucan with approximately one branch at two main chain glucosyl units at each C-6 position, and OL-2-III was a (1 --> 3)-beta-D-glucan with approximately one branch at twenty four main chain glucosyl units at each C-6 position (number of all main chain glucosyl units is on average). OL-2-I, OL-2-II and OL-2-III which were Smith-type degradation products of OL-2, showed potent antitumor activity against the solid form of sarcoma 180 in ICR mice. These results indicated that the degree of beta-linked branching at position 6 was remarkably related to the antitumor activity.
引用
收藏
页码:261 / 263
页数:3
相关论文
共 23 条
[1]   DEGRADATION WITH FORMIC-ACID OF CONFORMATIONALLY DIFFERENT (1-]3)-BETA-D-GLUCANS ISOLATED FROM LIQUID-CULTURED MYCELIUM OF GRIFOLA-FRONDOSA [J].
ADACHI, Y ;
OHNO, N ;
YADOMAE, T ;
SUZUKI, Y ;
SATO, K ;
OIKAWA, S .
CARBOHYDRATE RESEARCH, 1988, 177 :91-100
[2]   CHANGE OF BIOLOGICAL-ACTIVITIES OF (1-]3)-BETA-D-GLUCAN FROM GRIFOLA-FRONDOSA UPON MOLECULAR-WEIGHT REDUCTION BY HEAT-TREATMENT [J].
ADACHI, Y ;
OHNO, N ;
OHSAWA, M ;
OIKAWA, S ;
YADOMAE, T .
CHEMICAL & PHARMACEUTICAL BULLETIN, 1990, 38 (02) :477-481
[3]  
ADACHI Y, 1989, CHEM PHARM BULL, V37, P1858
[4]  
CZOP JK, 1985, J IMMUNOL, V134, P2588
[5]  
HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205
[6]  
JANUSZ MJ, 1989, J IMMUNOL, V142, P959
[7]  
KNOPSKI Z, 1991, SCAND J IMMUNOL, V33, P297
[8]  
KURACHI K, 1990, CHEM PHARM BULL, V38, P2527
[9]  
MIYAZAKI T, 1974, CHEM PHARM BULL, V22, P2058
[10]  
MIYAZAKI T, 1980, CHEM PHARM BULL, V28, P3118